For people with alopecia areata who have been prescribed a JAK inhibitor, getting the prescription may be only the first step. Insurance coverage, prior authorization, denials, appeals, specialty pharmacies, and out-of-pocket costs can all stand between you and your medication. The good news: you don’t have to navigate the process alone. NAAF and the manufacturers of FDA-approved JAK inhibitors for alopecia areata offer resources that may help you obtain and maintain access to your treatment. NAAF’s Understanding Insurance Coverage and Managing Treatment Access resource walks you through the process step by step, including prior authorization, denial and appeal, and authorization. It also includes practical tools such as sample patient testimonial letters and Letters of Medical Necessity, and recently published treatment recommendations that can help support an appeal, and links to pharmaceutical companies’ assistance programs. It’s important to know: Don’t take the first “no” as a final decision. An initial denial does not necessarily mean you won’t be able to get your medication. Many people are unaware that they can appeal a denial, and very few actually take steps to do so. But studies show that those who do appeal have a 75%+ chance of approval. Your healthcare provider’s office can review the reason for the denial and work with you to appeal the insurer’s decision. Depending on the circumstances, an appeal may include additional medical records, documentation of previous treatments, a Letter of Medical Necessity, and other information supporting your need for treatment. Pharmaceutical companies want to help. The manufacturers of FDA-approved JAK inhibitors for alopecia areata offer patient support programs that can help patients and healthcare providers navigate access to treatment. These can include co-pay assistance, even for people with commercial insurance no matter their income status. The cost of many of these medications, even with insurance coverage, can reach thousands of dollars annually. Co-pay assistance programs work in partnership with your insurance provider to make co-pays more affordable – sometimes for $25 or less per month. You might be able to get medication even while appealing your insurer’s denial. If your insurance company denies coverage or there is a delay in approving your medication, you may be eligible to receive your medication at low or no cost from the manufacturer while you and your healthcare provider work through the prior authorization or appeals process. This is commonly called bridge support because it helps “bridge” the gap between receiving your prescription and obtaining insurance coverage. Ask about support early. You don’t have to wait until there’s a problem to learn about these programs. When you and your healthcare provider decide that a JAK inhibitor is right for you, ask the office about enrolling in the manufacturer’s patient support program when the prescription is submitted. These programs can often help investigate your insurance benefits, track the prior authorization process, and identify potential access issues. Patient Support Programs for JAK Inhibitors (Note that each program has eligibility requirements and some restrictions.) Olumiant® (baricitinib) — Lilly Lilly Support Services™ for Olumiant® can help patients understand insurance coverage, coordinate with healthcare providers and specialty pharmacies, and explore savings and affordability options. Eligible commercially insured patients may also qualify for savings assistance, including assistance when their insurance does not cover Olumiant. Litfulo® (ritlecitinib) — Pfizer Litfulo offers savings and support, and Pfizer Dermatology Patient Access™ provides support throughout the insurance coverage process, including benefits investigation, prior authorization, and appeals assistance. Leqselvi™ (deuruxolitinib) — Sun Pharma Leqselvi Support™ provides patients with access and affordability support. Patients enrolled in the program are connected to a Patient Access Liaison who can help review insurance coverage, explain affordability options, and provide support throughout the process of obtaining Leqselvi. Eligible patients may also qualify for savings or other assistance through the program.
